About this trial
VN-RAPID is an open-label, multicenter, randomized controlled trial evaluating the safety and efficacy of in-hospital initiation and rapid up-titration of four-pillar therapy for hospitalized Asian patients with acute heart failure (AHF) and reduced ejection fraction (HFrEF). The study compares a standardized protocol of intensified treatment (high-intensity care arm) with usual care in patients with elevated NT-proBNP levels who are not on optimal HFrEF medications. The high-intensity care arm involves initiation of all four pillars of HFrEF therapy (RAS inhibitor, beta-blocker, MRA, and SGLT2i) before discharge, followed by a structured 6-week outpatient up-titration process with frequent follow-ups. The study aims for 75% of target doses for RAS inhibitors and beta-blockers, considering the lower blood pressure tendency in Asian populations. Participants will be followed for 180 days to assess clinical outcomes.
Eligibility criteria
Qualifiers
Hospital admission with diagnosis of acute heart failure assessed by clinical signs and symptoms of congestion and radiographic, biological tests (if admitted with acute coronary syndrome, required at least Killip class II or clear evidence of congestion on admission assessed by chest x-ray or lung ultrasound and/or pulmonary congestion requiring intravenous treatment)
Female or male patients ≥ 18 years old
Systolic blood pressure > 90 mmHg (at least 2 measurements on 2 different occasions) and
Heart rate ≥ 60 bpm (at least 2 measurements on 2 different occasions) and
Disqualifiers
Clearly documented intolerance to high doses of RASi/ARNi or beta-blockers
Absolute contraindication to usage of RASi/ARNi or beta-blocker or MRA or SGLT2i as per ESC 2021/ACC 2022 Heart failure guideline
LVEF >40% assessed by echocardiography on the latest measurement prior to discharge
Renal disease or eGFR < 30 mL/min/1.73m2 (as estimated by the CKD-EPI 2021 or the simplified MDRD) at Screening or history of dialysis.
Trial design
Treatments tested in this trial
- High intensity care
- Usual care
Treatment groups
Sponsors and collaborators
University Medical Center Ho Chi Minh City (UMC)
Lead sponsor
Momentum Research, Inc.
Collaborator
INSERM UMR-942, Paris, France
Collaborator
University of Medicine and Pharmacy at Ho Chi Minh City
Collaborator